logo
Twitter
Discord
Email
logo
Molina Healthcare, Inc.

Molina Healthcare, Inc.

NYSE•MOH
CEO: Mr. Joseph Michael Zubretsky
Sector: Healthcare
Industry: Medical - Healthcare Plans
Listing Date: 2003-07-02
Molina Healthcare, Inc. provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments: Medicaid, Medicare, Marketplace, and Other. The company served in across 19 states. The company was founded in 1980 and is headquartered in Long Beach, California.
Contact Information
200 Oceangate, Suite 100, Long Beach, CA, 90802, United States
562-435-3666
www.molinahealthcare.com
Market Cap
$8.93B
P/E (TTM)
10.0
46.4
Dividend Yield
--
52W High
$359.97
52W Low
$133.40
52W Range
14%
Rank29Top 12.7%
5.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$11.48B+11.00%
4-Quarter Trend

EPS

$1.51-73.32%
4-Quarter Trend

FCF

-$163.00M-119.45%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Q3 Revenue Growth Total revenue reached $11.48B USD for Q3 2025, marking a 12% increase over $10.34B USD reported in Q3 2024.
Net Income Decline Q3 2025 net income was $79M USD, significantly down 76% compared to $326M USD reported in Q3 2024.
Membership Base Expansion Total membership reached 5.63M members as of September 30, 2025, growing 0.5% from the prior year period.
Improved Operating Efficiency G&A expense ratio improved to 6.4% in Q3 2025, down from 6.5% in Q3 2024, showing operating discipline.

Risk Factors

Medical Cost Ratio Spikes Consolidated MCR rose 340 basis points to 92.6% in Q3 2025, reflecting challenging medical cost trends across segments.
YTD Profitability Pressure Nine-month net income fell to $632M USD in 2025 from $928M USD in 2024, driven by lower operating income.
Regulatory Uncertainty Risks Implementation of OBBBA law expected to reduce Medicaid Expansion enrollment by 15% to 20% over the next few years.
Increased Interest Expense Q3 interest expense rose to $49M USD from $29M USD year-over-year due to new borrowings executed in 2025.

Outlook

ConnectiCare Acquisition Integration Integration of ConnectiCare acquisition is underway, impacting depreciation and amortization expenses for the current period.
New State Contract Wins Secured new Medicaid contracts in Mississippi starting July 2025 and Nevada expected to commence January 2026.
Stock Repurchase Program $500M USD remains available under the April 2025 authorization for common stock purchases through December 31, 2026.
Evaluating New Accounting Update Evaluating impact of ASU 2025-06 regarding internal-use software costs; early adoption is permitted.

Peer Comparison

Revenue (TTM)

Molina Healthcare, Inc.MOH
$44.55B
+13.7%
DaVita Inc.DVA
$13.32B
+5.1%
The Ensign Group, Inc.ENSG
$4.83B
+17.5%

Gross Margin (Latest Quarter)

Exelixis, Inc.EXEL
96.9%
+0.1pp
BioMarin Pharmaceutical Inc.BMRN
82.0%
+7.2pp
Moderna, Inc.MRNA
79.6%
+7.3pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
PEN$12.41B75.513.1%12.4%
EXEL$12.40B18.331.6%6.3%
MRNA$12.19B-3.9-31.4%5.7%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.0%
Moderate Growth
4Q Net Income CAGR
-32.0%
Declining Profitability
Cash Flow Stability
25%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 4, 2026
|
EPS:$0.43
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 23, 2025|
    Revenue: $11.48B+11.0%
    |
    EPS: $1.51-73.3%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 24, 2025|
    Revenue: $11.43B+15.7%
    |
    EPS: $4.76-8.5%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: Apr 24, 2025|
    Revenue: $11.15B+12.2%
    |
    EPS: $5.47+5.2%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 11, 2025|
    Revenue: $40.65B+19.3%
    |
    EPS: $20.52+9.7%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 24, 2024|
    Revenue: $10.34B+21.0%
    |
    EPS: $5.66+33.5%
    Meet

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Jul 25, 2024|
    Revenue: $9.88B+18.6%
    |
    EPS: $5.20-3.0%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: Apr 25, 2024|
    Revenue: $9.93B+21.9%
    |
    EPS: $5.20-6.0%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 13, 2024|
    Revenue: $34.07B+6.6%
    |
    EPS: $18.71+36.6%
    Beat